Neoadjuvant Capecitabine, Gemcitabine/Capecitabine Effective for Pancreatic Adenocarcinoma
the Cancer Therapy Advisor take:
Pancreatic adenocarcinoma is diagnosed in more than 45,000 people each year, and less than 6% of these patients are expected to survive past 5 years; therefore, effective, safe treatments for the disease are paramount.
In an article recently published in the journal Cancer, researchers from Columbia University aimed to determine whether the neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) and gemcitabine and capecitabine (GX) with radiation therapy (RT) was appropriate for patients presenting with locally advanced, unresectable disease.
The study protocol was designed for GTX to shrink the tumor, thus allowing the tumors to be resected; GX with RT were then given to those presenting with arterial involvement to eradicate any tumor on the arterial margins. The researchers found that in 45 patients who were given either GTX or GX/RT, the treatments were tolerated with expected side effects.
In patients with arterial involvement who underwent resection, 20 achieved R0 (complete) resections. In the 11 patients with venous-only involvement, 8 achieved R0 resections and 3 complete pathologic response. Seventy-one percent of the total patients in this study were alive after 1 year, and median survival was 29 months. Thirteen patients have not relapsed, and in the venous arm, median survival has not been reached.
The authors concluded that GTX and GX/RT are effective regimens that can be safely administered in this setting, resulting in a high response rate and prolonged overall survival.
Neoadjuvant gemcitabine, docetaxel, and capecitabine was appropriate.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy